Fundraising FoxAjax Therapeutics Inc.
Unicorn exit · $2.3BAcquiredNew York, US · Founded 2019 · Delaware corporation · 5 known investors
Find your way into Ajax Therapeutics Inc.
Sign up to see every warm intro you have to Ajax Therapeutics Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ajax Therapeutics Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Eli Lilly and Company April 2026 · $2.3B (up to $2.3 billion, including upfront and milestone payments) · source ↗
Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery. Its lead candidate, AJ1-11095, is in a Phase 1 clinical trial for patients who have failed currently available Type I JAK2 inhibitors.
Founders & leadership
Ajax Therapeutics Inc. was founded in 2019 by Martin Vogelbaum.
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$140.4M disclosed across 3 rounds · 2019–2024
▶$95MraisedMay 2024 · 21 investors · BiotechnologyRule 506(b)
- Martin VogelbaumExecutive Officer, Director
- Ross LevineDirector
- Scott PlatshonDirector
- Ramy FaridDirector
- Offering amount
- $95M
- Amount sold
- $95M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$37.4MraisedJun 2021 · 14 investors · BiotechnologyRule 506(b)
- Martin VogelbaumExecutive Officer, Director
- Ross LevineDirector
- Ramy FaridDirector
- Scott PlatshonDirector
- Offering amount
- $40M
- Amount sold
- $37.4M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$8MraisedJun 2019 · 6 investors · OtherRule 506(b)
- Martin VogelbaumExecutive Officer, Director
- Ross LevineDirector
- Ramy FaridDirector
- David SchnellDirector
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Ajax Therapeutics Inc..
Frequently asked questions
- What does Ajax Therapeutics Inc. do?
- Ajax Therapeutics is a biotech company developing Type II JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPNs), including myelofibrosis, using computational chemistry and structural biology in its drug discovery. Its lead candidate, AJ1-11095, is in a Phase 1 clinical trial for patients who have failed currently available Type I JAK2 inhibitors.
- Who founded Ajax Therapeutics Inc.?
- Ajax Therapeutics Inc. was founded by Martin Vogelbaum in 2019.
- Who are Ajax Therapeutics Inc.'s investors?
- Ajax Therapeutics Inc.'s investors include Inning One Ventures, EcoR1 Capital, RA Capital, Revelation Partners, Vivo Capital.
- How much funding has Ajax Therapeutics Inc. raised?
- Ajax Therapeutics Inc. has disclosed $140.4M raised across 3 rounds.
- Where is Ajax Therapeutics Inc. headquartered?
- Ajax Therapeutics Inc. is headquartered in New York, US.